With the advent of a market-orientated economy, the medicinal plants wealth of the Himalaya has become a high price commodity. As a result, many wild populations of valued medicinal plants are declining due to over-harvesting. In order to prevent the further loss of medicinal plants in the wild and, at the same time, to meet the demands of pharmaceutical companies and herbal healers, attempts are being made at various levels (e.g. farmers and government organisations) to cultivate these species. Unfortunately, these cultivation efforts are not entirely successful for many reasons, including the specific ecological requirements of many Himalayan medicinal plant species. Moreover, there are many other constraints in the development of the Himalayan medicinal plants sector. The present study examines such constraints and also identifies the prospects in view of developing and managing the medicinal plants sector.
Introduction
The history of herbal medicine is as old as the social and cultural groupings of human beings (Schultes, 1996) . Medicinal plants have long played a central role in the treatment of existing and new-born diseases by providing raw material to the pharmaceutical industries and traditional herbal healers (Kala et al., 2004) . In addition, the cosmetics has estimated that the present demand for medicinal plants is about US $14 billion a year. The demand for medicinal plant-based raw materials is growing at the rate of 15-25% annually and, according to the WHO estimates, the demand for medicinal plants is likely to increase to US $5 trillion in 2050 (Sharma, 2004) .
The actual demand, however, will be even greater than the data suggest as a sizeable proportion of medicinal plant material is used for domestic consumption and a large part of the trade in medicinal plants is illegal, thus unrecorded. The leading suppliers of medicinal plants are: China, Singapore, Brazil, India, and Egypt (Lange, 1997) . International demand is largely from the US and the EU, with Germany as the leading trade centre (KIT, 2003) . According to a survey, in Member States of the EU about 1400 herbal preparations are used for therapeutic purposes. There are about 7000 compounds and 47 modern pharmaceutical plant based drugs already in the world market and the predicted 328 drugs (yet to be discovered) have a market potential of US $147 billion. In its first year, sales of the anti-cancer drug taxol from the Taxus species fetched more than US $2 billion (Crook and Clapp, 1998; CTA 2002; Planning Commission 2000) . Such popularity of plant-derived products in healthcare reflects their increasing acceptance across the world.
This increasing demand for plant-based drugs is, however, causing the heavy pressure on some selected high value medicinal plant populations in the wild . Many Himalayan medicinal plant species have slow growth rates, low population densities and narrow geographic ranges (Dhyani and Kala 2005; Kala, 1998) ; hence they are more prone to extinction (Jablonski, 2004) . On the other hand, the indigenous knowledge on the use of lesser-known medicinal plants is declining sharply. Realising the importance of medicinal plants in recent years, the central and state Governments of India have shown an interest in the medicinal plant sector, which they wish to strengthen in order to create additional income and employment opportunities. In view of the renewed interest in the use of plant based drugs, overexploitation of selected medicinal plant species and escalating pressures on the widely used medicinal plants of the Himalaya, it is imperative to review the status of existing knowledge on the medicinal plants of this region.
To ensure the long-term sustainability of medicinal plants as an essential commodity for healthcare, it is important to regulate the medicinal plant stock. Identification of traditional and modern tools used in the conservation of medicinal plants will be a step forward in strengthening the medicinal plant sector. The immediate need is to explore different tools for strengthening the medicinal plant sector including biotechnology, community conservation, bio-prospecting and ways to prevent bio-piracy. In order to meet these objectives the present paper explores various challenges for strengthening and managing the medicinal plant sector. In addition, the paper highlights the various prospects for advancing the medicinal plants sector by using both conventional and modern tools such as biotechnology, community decision mechanisms and wise use of indigenous technologies for the sustainable and economically viable development of the Indian Himalayan communities. In general, the present study discusses four major questions:
Is collection for commercial purposes a road to medicinal plant extinction in the wild?
Will community-based conservation sustain this precious stock?
To what degree can biotechnology solve the setbacks?
Are bio-prospecting and bio-piracy a threat to the traditional and indigenous knowledge of medicinal plants?
2 Is collection for commercial purposes a road to medicinal plant extinction in the wild?
Over years of observations, the indigenous communities of the Himalaya have developed their own knowledge on how to maximise the harvesting of desired plant parts while minimising the pressure on the wild stock. They mostly collected mature plants.
Underground plant parts (root and rhizomes) of perennials were generally gathered after two or three years of growth. Tubers and bulbs of the annual species were collected at the end of the flowering or fruiting. Young leaves of medicinal plants were gathered throughout the growing period to maximise the quality of active compounds. When the whole herb was required for medicine, the herb was collected at the beginning of the flowering stage. Fruits and seeds of medicinal plants were collected when mature. The bark was collected when trees and shrubs began to bud in spring and after leaves shed in autumn (Kala 2002; Kaul, 1997) . It was perceived that the mistaken identity of plants during collection, particularly of plants with phenotypic similarity, might lead to accidental poisoning; therefore only the trained herbal healers used to collect the medicinal plants. After collection, proper care was taken to dry and process the material. At least 90% of the plant species used in various herbal industries is extracted from the wild, the majority of which comes from the sub-alpine and alpine regions of the Himalaya (Anon, 1997) . With the changing life style and socio-economic values, the greed to over-harvest the valuable medicinal plants of the Himalaya for immediate cash by selling to any prospective buyer has superseded the traditional values. Though laws have been enacted to prevent over-harvesting, illegal collection is continued across the Himalayan region (Kala, 2002 (Kala, , 2003a . With escalating competition to collect large quantities of medicinal plants, influential people even hire labourers from outside. These labourers have no training in traditional collection techniques.
The ruthless and unscientific collection of these high value medicinal plants is one of the causal factors for their rarity and making an imbalance in the demand and supply. From the North West Himalaya, the supply of the few and important rare medicinal plant species, Dactylorhiza hatagirea, Gentiana kurroo, Aconitum heterophyllum and Picrorhiza kurrooa, for example, is about 100 tonnes per year for each species. The demand of Dactylorhiza hatagirea alone is 5000 tonnes per year. Similarly, the annual demand of Gentiana kurroo and Picrorhiza kurrooa is 5000 tonnes per year for each and the demand for Aconitum heterophyllum is 1000 tonnes (Mishra, 1998) . This trend has led to over-exploitation and is one of the reasons for the documented extinction of more than 19 plant species in the wild in India, 41 species suspected of having recently become extinct, 152 species in danger of extinction if the causal factor continues, 102 species believed to have move to the next (higher) category of rarity and 251 species at risk and now restricted to limited areas (Walter and Gillett, 1998) . Similar patterns have taken shape around the world. In the US, for example, 29% of the country's 16,000 plant species are extinct, endangered, vulnerable and rare due to various land-use operations (Robbins, 2000) .
However, there are reports portraying the present assessment as ambiguous and, thus, suggesting the need for more in-depth studies on the current population density of the concerned threatened species in the wild (Kala, 2004b) . The potential erosion of genetic variability within each species must be studied to determine acceptable levels of rarity. Based on the four selected prioritised categories, such as endemism, use value, mode of harvesting and rarity status, Kala et al. (2004) have identified 17 plant species of the Himalayan region for priority attention with respect to their conservation and cultivation ( 
Will community-based conservation sustain this precious stock?
Twenty one national parks and 86 wildlife sanctuaries have been set aside for the in-situ conservation of biodiversity across the Indian Himalaya. However, due to rising conflicts among conservationists on pro-park and pro-people views, the Protected Area networks are in a state of crisis (Madhusudan and Raman, 2003; Wells, 1992) . The Government of India has also enacted export restrictions on 29 plant species to prevent their further loss in the wild. However, the sustainability of these species cannot be achieved merely by promulgating a ban on export or by fencing areas rich in medicinal plants (Purohit, 2004) . The establishment of Medicinal Plants Conservation Areas (MPCA) in various sectors of the Himalaya could be a step forward in conserving medicinal plants and also in mitigating the conflicts between these two communities (Kala, 2000) . The buffer zone areas could be selected for medicinal plants cultivation. At the same time, giving ownership of natural resources to local people and encouraging profitable uses of Jain (1991) those resources may provide a powerful incentive for both medicinal plant conservation and sustainable economic development of the local people (Child, 2002) . Sustainable harvesting combined with cultivation can improve yields in buffer zones and it may also reduce pressure in the core zone of the Protected Areas (Kala, 2005a) . It has been shown that under cultivation and in a consolidated area the plants give a better yield, are easier to manage for diseases, are easier to harvest quickly and predictably and assure the supply of quality raw material to the industries (Kala, 2002 (Kala, , 2005b Kaul, 1997) . Besides, cultivation also permits better species identification, improved quality control, increased prospects for genetic improvements and the production of uniform material from which standardised products can be consistently obtained. The MPCA may ensure the autonomous development of a rural community by enhancing the people's income. This way they can decide themselves how to use their assets and resources, for which market they wish to produce and by which services they need to achieve their goals. It also enables them to restore resources depleted by overuse, assume the long term supply of resources, regulate national and international trade by assuring a continuous supply of quality material and ensure the conservation of not only the species concerned but also its associated species and ecosystems (Kaul, 1997; KIT, 2003) . The role of policy makers in achieving such goals is equally important. They should develop some favourable environment in terms of legislation, taxation and communication for growers to create a dynamic exchange of products and capital between producers and traders. This warrants a new role for the government that not only regulates but also stimulates and provides services that meet the demands of the productive and commercial stakeholders (KIT, 2003) . The number of linkages in medicinal plants supply, process, drug formulation, trade, transport and the retail industry can be used to generate employment. Since women are engaged in the farming and collection of medicinal plants across the Himalaya, the promotion of medicinal plants cultivation could also help to empower women by enhancing their source of revenue. The available rural technologies for the farming of some valuable medicinal plant species (Table 3) can be made useful for their large-scale cultivation.
The traditional beliefs of native communities with respect to the conservation of medicinal plants should also be taken into account. The practitioners of Ayurveda use to worship many medicinal plant species before their harvest from nature. Many medicinal plant species are medicinal as well as religious and many medicinal plant species are worshipped as a symbol of local Gods and Goddesses in the Himalayan region (Table 4) . Hence, there is a general fear in indigenous societies towards the over-exploitation of such medico-religious plant species. Generally, most of these medico-religious plant species are rare in nature, Ficus religiosa, Ficus benghalensis, Zanthoxylum armatum and Saussurea obvallata, for instance. Such a traditional belief in the society is a way of conserving the useful natural resource, which needs to be kept alive in order to sustain the medicinal plant's populations. Hitherto, only 1% of all identified plant species have been screened for active compounds useful for therapeutic purposes (CTA, 2002) . Attempts have been made to derive compounds of commercial importance from the Himalayan medicinal plants. In-vitro plant tissue culture technology was developed with the hope of obtaining desired products when plant materials are rare and difficult to acquire. Chemical synthesis is not possible and the costs of production to meet demand are high. Considering these challenges the development of in-vitro technology has grown and is being applied with some of the threatened medicinal species of the Himalayan region, including: Picrorhiza kurrooa, Podophyllum hexandrum, Heracleum candicans, Rheum emodi, Arnebia benthamii, Taxus baccata, Hedychium spicatum, Nardostachys grandiflora, Angelica glauca and Aconitum heterophyllum. However, this approach has not been very encouraging as the yield is too low for commercial feasibility. In spite of the high cost and slow pace to achieve success in biotechnology, if we want a large and continuous supply it is necessary to invest more.
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A considerable amount of research is still paramount to explore the potential for tissue culture to be commercially viable. Globally, only a few products such as shikonin and ginseng are successfully manufactured on a larger scale. Strategies and treatments, such as biotransformation, cell permeabilisation, immobilisation, elicitation and hairy root culture show promise for other products to reach a commercial scale. In addition, protoplast fusion and somatic hybridisation, media composition and selection of cell lines and changing media composition can be adopted to improve the quality and quantity of biosynthetic cell culture products (Khan and Khanum, 2000; Lozoya, 1994) . The culture conditions have also been reported to influence the amount of drugs obtained in culture. For example, the amount of ginseng produced doubled when the culture was rotated on a horizontal clinostat instead of being kept stationary (Zhao and Cai, 1998) . Some have proposed that cellular factories using recombinant DNA technologies may develop new therapeutics in the future. If such modern technologies are successfully applied to the medicinal plants of the Himalaya, they may help improve yields to meet the commercial demand of required products. Some governmental and non-governmental organisations have focused attention on improving the medicinal plant sector. However, of the total 1420 projects sanctioned by some major organisations, the share of the Himalayan region was only 6.3%, with only one project allocated to medical science (Jain and Kumar, 1994) . Funding must be improved in order to meet the expected results from the medicinal plants sector.
Are bio-prospecting and bio-piracy a threat to the traditional and indigenous knowledge of medicinal plants?
With the globalisation of useful bio-resources such as medicinal plants, a fear of bio-piracy has increased since the patent drama that took place when the US Patent and Trademark Office granted a patent on turmeric powder for use in healing wounds. This patent was later successfully overturned by India. A similar problem was faced by India in the case of the Neem (Azadirachta indica) patent. The overturning of the turmeric patent was the first case in which a Third World country succeeded in its objection to a foreign patent on the grounds that it was based on traditional knowledge known to the country for generations and that its various uses had been previously documented in various historical documents. It was a landmark victory in the battle against bio-piracy (Udgaonkar, 2002) . Unfortunately, there is a wide gap between developing and developed nations on patenting the products. For instance, out of 3,125,603 patents filed over 91 countries only 301,177 or 9.6% are registered in developing countries, with the rest in industrialised countries. Of these, only 0.2% of the total and 2.3% of those registered in developing countries belong to residents and 97.7% of the total patents filed so far are in the name of non-residents, who apply only to control export markets in developing countries (Egziabher, 2003) . The approaches for awarding patents on medicinal plants in the US, Europe, Canada and Andean countries are different and, thus, illustrative sui generis systems from the US, Europe and India are contrasted (Koo et al., 2004) . In most countries, plants and inventions directed to plants and plant products such as seeds, flowers, gums and resins are not eligible for filing a patent. However, in the US, any living organism derived by human invention, such as by breeding or by laboratory-based manipulation can be filed for awarding patent. Developing countries and many scientists who want to exploit medicinal plants demand more specified rules on the record of the nativity of samples and the sharing of their benefits between the nations of origin, the inventor and the commercial sponsors. However, US Patent authority is not inclined to accept such rules. These conflicts have frustrated many scientists who believe that natural products remain the most promising source of new drugs.
On patent issues, India has chosen a more expansive approach. The Indian Protection of Plant Varieties and Farmers Rights Act 2001 recognises the contribution of professional plant breeders and farmers who actively participate in breeding programmes. This Act contains provisions for benefit sharing whereby local communities are acknowledged as contributors of plants (Koo et al., 2004) . However, globally most of the issues with reference to protecting the legal status for indigenous knowledge and to compensating the indigenous herbal practitioners for that knowledge are extremely complicated. There are arguments on the present state of compensation or benefit sharing under the intellectual property rights, which is being considered a new legal form of bio-piracy by one group, whereas others advocate that intellectual property right is a legal tool to protect the rights of knowledge holders (Green et al., 1999) .
Will recording traditional and indigenous knowledge prevent bio-piracy? Today, the conservationists and indigenous communities around the world are in search of the feasibility and applicability of this question. The lack of legal protection for the therapeutic properties of numerous medicinal plants of the Himalaya has made indigenous knowledge vulnerable to bio-piracy, as illustrated by the cases of patents for products. Knowledge of the traditional utility of a plant is not patentable by indigenous practitioners since the criteria of patentability are: novelty non-obviousness industrial application.
Being traditional is, by definition, not novel even though it is based on innovation and the indigenous medical system is not industrial (Shiva, 1998) . Together this makes the traditional knowledge of plants for therapy most susceptible to bio-piracy. There are reports which have attracted the attention of developing nations by stating that patent monopolies on plant and plant products threaten to harm the developing nations in three major ways. Firstly, by raising prices. Secondly, by blocking local production when the patent owner so chooses and thirdly, for agricultural varieties, by not welcoming farmers to continue breeding them as has been done for thousands of years. The problem of patenting the medicinal plants should be resolved on the basis of human respect, respect by communities of one another, respect by individual people within communities and respect for different societal traditions.
Discussions and conclusions
There are some inherent problems in the medicinal plants sector (Table 5) , including the proper identification of plant species that have multiple local names in the traditional medical systems. Due to the scarcity of data on the maturity period of many medicinal plants collected from the wild, there are uncertainties with the production of quality chemical compounds from these plant species (Kaul, 1997; Khan and Khanum, 2000) . It is believed that medicinal plants collected from the wild have greater medicinal benefits than those cultivated commercially as crops. Although there are many advantages of cultivation, the success rate of many species is low due to their specialised environmental requirements. Worldwide only 0.05% of plant species have been domesticated out of the total known wild species of higher plants and, in most cases, the obstacles in cultivation lay with the species itself not with the local people (Diamond, 2000) . There is an obvious need to develop proper policies for the sustainable and economically viable development and management of the medicinal plant sector as there is an increasing pressure on medicinal plants due to various land-use practices from the conversion of natural habitat to over-exploitation for commercial purpose. With the growing consumer interest in plant-based medicines, this threat is likely to increase. For example, to treat a single cancer patient requires 2 grams of taxol, which is extracted from the bark of approximately ten Taxus trees (Benson, 1999) . Biotechnology may help in this regard as it directly and indirectly enables conservation strategies and, at the same time, allows economically significant species to be both utilised and protected. Although there are differences between the major philosophies of medicinal plant commercialisation and conservation, their overall aim attached with human welfare can be used for positive gains (Table 6 ). While formulating policies for improving the medicinal plants sector, it is imperative to take advantage of local people's in-depth traditional knowledge on the use and conservation of many locally available medicinal plant species (Fazey et al., 2004; Kala, 2003b; Kala et al., 2006) . Their perspectives can facilitate ways of allocating scarce resources among competing demands. There are opportunities to incorporate the conservation policies for medicinal plants within the framework of existing legal instruments, such as the Convention on Biological Diversity and Convention on International Trade of Endangered Species. Policy should address the proper linkages among industries, research institutes and farmers. To overcome the problems faced by farmers, the research should be on-farm orientated rather than laboratory-based approaches. The promotion of community-based conservation through the establishment of MPCA and the dissemination of awareness among the various stakeholders (e.g. herb cultivators, herb gatherers, herbal practitioners and traders) about sustainable harvesting techniques and processing through training can be a step forward in the conservation of medicinal plants. The majority of medicinal plant species are harvested from wild populations. It is unlikely that more than a few economically valuable species will be cultivated on a commercial scale or supplied through biotechnologies. The industries and consumers should take the greater responsibility and bear a greater share of the cost of conservation. The diffusion of any available scientific knowledge on the medicinal plants should be made operational via better networks of communication. For regulating the harvest of common wild medicinal plants and also for preventing illegal trans-boundary trade between different Himalayan states, a Himalayan Medicinal Plants Board should be set aside that looks after all State Medicinal Plants Boards and also help them in the exchange of rural and modern agro-technology, development of medicinal plants nurseries, framing policies for sustainable utilisation and legalised trade in Himalayan medicinal plants. Ethnopharmacologists should revalidate and promote traditional ways of curing. At the same time, people should be made aware of the fact that continued access to herbal medicines is dependent on the continued existence of these plants and the ecosystem in which they flourish, therefore they should collectively put efforts into the conservation of this valuable bio-resource. Fazey et al. (2004) The future of the Himalayan societies, like all other societies of the world, is inextricably interwoven with its ability to manage its own biodiversity, especially that of medicinal value. Such importance amply justifies increased national and international funding of measures that lead to the appropriate management of this resource. Attempts should be made by all stakeholders to encourage, recommend and promote the inclusion of herbal medicines in national healthcare programmes because such medicine is easily available at a price within the reach of the common people and is time tested and considered to be much safer than the modern synthetic drugs. To strengthen the herbal medicine village, clinics should be promoted for providing rural healthcare and enhancing local livelihood opportunities. To promote and also to regulate the various herbal healthcare programmes around the world there is a need to bring the various stakeholders of the medicinal plant sector under an umbrella by creating a World Herbal and Medicinal Plants Trade Organisation. The growing human population, most of which is poor, increases the importance of plant-based medicine due to their low prices. To maintain the health of a growing human population, various herbal formulations prepared by traditional herbal healers should be renewed by testing their efficacy. Such scientifically prepared medicine will project herbal medicine in a proper perspective and help capture a wide global market. The successful establishment of the medicinal plant sector may help raise rural employment in the developing countries, boost commerce around the world and contribute to the health of millions.
